Arya News - Multiple new clinical trials are underway to evaluate if various treatments will prove effective against the Bundibugyo Ebola virus in the DRC. A
For the first time since the Ebola outbreak began in the Democratic Republic of Congo, multiple new clinical trials are underway or soon will be to evaluate new therapies that could improve survival.
New treatments are critical because the ongoing Ebola outbreak is caused by the Bundibugyo species of Ebola which does not have any approved vaccines or therapies that can mitigate its spread. This specific virus has been difficult to contain, with now well over 500 confirmed deaths and 1,561 confirmed cases, according to the CDC . Armed conflict, displacement, attacks on healthcare facilities and limited contact tracing have complicated outbreak control efforts.
The clinical trials will test two separate drugs, MBP-134 and remdesivir, for efficacy in treating the Bundibugyo Ebola virus. Trials will test both drugs alone and as part of combination therapy. In addition, a separate trial will test whether obeldesivir , an antiviral oral pill, can prevent those that have been exposed to the virus from contracting the disease. All trials represent a collaborative effort between the WHO, Africa CDC, universities and various non-profit organizations.
About Our Ads
Yahoo! US Politics 2024 Election World Health Science The 360 Contact Us Originals Help Share Your Feedback About Us About Our Ads Site Map Follow us on
Download our app
© 2026 Yahoo. All rights reserved.
View comments